Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach.
Jelena Belic, Marina Koch, Peter Ulz...
https://pubmed.ncbi.nlm.nih.gov/25896989/Actively Recruiting
Led by Nick Beije · Updated on 2025-12-03
400
Participants Needed
26
Research Sites
N/A
Total Duration
Researchers are evaluating a shorter treatment duration with androgen receptor pathway inhibitors ARPIs, specifically Apalutamide or Enzalutamide, in patients with low-volume hormone-sensitive metastatic prostate cancer. This phase 3 clinical trial aims to determine if stopping ARPI therapy after 12 months, with the option to restart if the cancer progresses, is not worse than continuing ARPI treatment. The goal is to reduce side effects and costs while maintaining effective disease control. Participants will be randomly assigned after completing 12 months of ARPI treatment to one of two groups one group will continue androgen deprivation therapy ADT combined with ARPI, while the other will stop ARPI after 12 months but may restart it if a confirmed rise in prostate-specific antigen PSA occurs. The PSA confirmation sample must be taken at least four weeks after the initial rise. Treatment will be monitored closely according to these protocols. During the study, participants will be followed for up to 6 years, including 5 years after randomization to track clinical progression-free survival. Researchers will regularly assess disease status, treatment effects, and possible side effects. The study includes regular visits and monitoring to evaluate how long patients remain free from disease progression while comparing the two treatment approaches.
CONDITIONS
Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
D
Dr. N. Beije
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nick Beije
Lead Sponsor
Stichting Treatmeds
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 weeks before enrollment
Participants start androgen deprivation therapy (ADT) within 6 weeks before inclusion and are prepared for the trial treatment.
Visits as needed before randomization
Duration - Up to 12 months or until progression, depending on treatment arm
Participants receive androgen deprivation therapy (ADT) combined with either 12 months of androgen receptor pathway inhibitor (ARPI) or continued ARPI until disease progression.
Visits scheduled according to treatment protocol during therapy
Duration - Up to 5 years after treatment ends
Participants are followed for clinical progression-free survival and other outcomes for up to 5 years after treatment.
Periodic visits for monitoring and assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jelena Belic, Marina Koch, Peter Ulz...
https://pubmed.ncbi.nlm.nih.gov/25896989/Matthew R Smith, Fred Saad, Simon Chowdhury...
https://pubmed.ncbi.nlm.nih.gov/29420164/Christopher P Evans, Celestia S Higano, Thomas Keane...
https://pubmed.ncbi.nlm.nih.gov/27006332/Cora N Sternberg, Karim Fizazi, Fred Saad...
https://pubmed.ncbi.nlm.nih.gov/32469184/Nicholas D James, Matthew R Sydes, Noel W Clarke...
https://pubmed.ncbi.nlm.nih.gov/26719232/Jingsong Zhang, Jessica J Cunningham, Joel S Brown...
https://pubmed.ncbi.nlm.nih.gov/29180633/Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci...
https://pubmed.ncbi.nlm.nih.gov/29384722/Nicholas D James, Johann S de Bono, Melissa R Spears...
https://pubmed.ncbi.nlm.nih.gov/28578639/Pauline A J Mendelaar, Debbie G J Robbrecht, Maud Rijnders...
https://pubmed.ncbi.nlm.nih.gov/35181986/Gillian Vandekerkhove, Werner J Struss, Matti Annala...
https://pubmed.ncbi.nlm.nih.gov/30638634/Nick Beije
Lead Sponsor
Stichting Treatmeds
Collaborating Sponsor